Operations move into execution
A GMP site opens. Portfolios and trials reset.
Bio-Techne opens a cell-therapy materials facility while Viatris, ADC Therapeutics, Nuevocor and Edgewise move capital and programs into new operating phases.
JobReports original SVG editorial illustration
5
verified developments
5
public employer boards refreshed
5
current openings curated
24h
news window to 10:30 AM ET
Editorial counts only. The job shortlist comes from five named public employer boards and is not a national inventory or market-wide hiring measure.
Cell therapy / GMP manufacturing
Bio-Techne brings a purpose-built Bristol facility into operation
Bio-Techne opened a 10,000-square-foot facility in Bristol, United Kingdom, for Good Manufacturing Practice-grade small molecules used in cell-therapy development. The site has five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms for manufacturing and product handling.
The company said the facility is fully operational and already manufacturing GMP-grade materials. It joins capabilities in Minneapolis and St. Paul as part of a network intended to support customers from discovery through clinical development and commercial production.
Why it matters
An operating cleanroom site creates a concrete setting for manufacturing, quality, analytical and supply work. Bio-Techne did not announce hiring tied to the opening, and the separate roles below are not presented as consequences of it.
Transaction / Pain portfolio
Viatris agrees to acquire Pacira for $1.65 billion
Viatris and Pacira entered a definitive agreement for Viatris to buy all outstanding Pacira shares for $36.50 each in cash, an aggregate equity value of $1.65 billion. Pacira brings the marketed pain medicines EXPAREL and ZILRETTA plus a clinical pipeline.
The companies expect closing by the end of 2026, subject to tender and regulatory conditions. Viatris specifically cited Pacira's U.S. commercial, market-access, medical-affairs and R&D capabilities, but integration and workforce outcomes have not been announced.
Financing / Oncology operations
ADC Therapeutics restructures financing around a 2029 runway
ADC Therapeutics announced an $86.6 million private placement, a revised royalty agreement and a refinanced senior secured loan. It expects the combined changes to reduce leverage and extend its cash runway into 2029.
The company plans to use proceeds to continue ZYNLONTA studies, including Phase 3 work in diffuse large B-cell and marginal-zone lymphomas, while also funding working capital. The transactions remain subject to their stated closing conditions.
Gene therapy / First-in-human
Nuevocor doses the first patient and receives Fast Track status
Nuevocor dosed the first patient in SUNBEAM-LMNA, a Phase 1/2 trial of the one-time AAV9 gene therapy NVC-001 in adults with LMNA dilated cardiomyopathy. The FDA also granted NVC-001 Fast Track designation.
The open-label, single-ascending-dose study will test three dose levels, with safety and tolerability as its primary objective. This is a trial-start milestone and review designation, not evidence of efficacy or approval.
Cardiometabolic / Phase 2
Edgewise starts a 90-person HFpEF study
Edgewise dosed the first patient in EQUINOX-HFpEF, a randomized, double-blind Phase 2 trial of EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction.
The study is expected to enroll about 90 adults across two dose groups and placebo for up to 12 weeks, evaluating safety, tolerability and biological effects. It moves the program into patient testing without establishing clinical benefit.
Public-board shortlist
Five current roles worth a closer look
These openings were visibly checked on their employers' application pages before publication. They are independent of the news above; no direct connection between an announcement and a listed role has been established.
Associate Director, Scientific Communications
Waltham, Massachusetts
Associate Director, Medical Affairs (Medical Scientific Liaison)
Remote
Clinical Trial Associate
Waltham, Massachusetts
Sr Director, Commercial Operations
South San Francisco, California
Senior Scientist, Computational Biology
Somerville, Massachusetts
Practical takeaway
Today's signals favor people who can turn a new operating phase into disciplined execution.
The facility opening, proposed acquisition and financing reset point to work around quality, integration, commercial operations and portfolio delivery. Two trial starts add demand for careful clinical execution. The five openings provide a separate current view across communications, field medical, trial operations, commercial leadership and computational biology from a deliberately bounded source set.
Explore previous briefings